1.
How can we identify patients with oligometastatic ovarian cancer who may benefit from local therapies?
ESGO 2026 Tumour board Session: Management of Oligometastatic Recurrent Disease in Ovarian Cancer
1 out of 3
2.
How can 3D reconstruction imaging improve surgical outcomes?
ESGO 2026 Scientific Session: Surgical Trends of the Future
2 out of 3
3.
Can radiotherapy serve as a curative approach in recurrent ovarian cancer, or is it purely palliative?
ESGO 2026 Tumour board: Management of Oligometastatic Recurrent Disease in Ovarian Cancer
3 out of 3